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Abstract
Background—The control rate for hypertension is unacceptably low worldwide, and poor 
adherence to medication is a primary reason.
Objectives—To evaluate the impact of full coverage for hypertension drugs on adherence to 
medication, medical costs, and hypertension control in Shandong Province, China.
Methods—In November 2009, we interviewed 110 hypertensive patients who had been 
participating in a free medication program since May 2008 and 241 hypertensive patients who 
were not participating. We used a 1:1 propensity-score matching technique to obtain matched 
samples of 102 program participants (intervention) and 102 nonparticipants (control). We used 
univariate analysis to compare patient drug-taking behaviors, medical costs, and hypertension 
control between the 2 groups.
Results—All intervention patients took ≥1 drugs for hypertension control and 93% of them took 
≥3 such drugs, 15 control patients (15%) did not take any, and only 39% took 3 or more (P <.001). 
Three-fourths (75%) of the intervention patients took the prescribed drugs regularly, whereas 66% 
of the control group (P = .034) did so. Participation in the program was associated with lower 
annual out-of-pocket medical costs both overall and for outpatient services (P <.001 for both).
Conclusions—Low-income rural residents in China receiving free drugs had enhanced 
medication adherence and reduced total medical costs. Providing hypertension drugs at no charge 
may be a promising strategy for preventing costly cardiovascular events associated with 
hypertension in China and other parts of the world with growing rates of cardiovascular disease.
Throughout the world, hypertension is the number one attributable risk factor for death, and 
its prevalence is increasing.1–4 A report for 2001 estimated that worldwide, 14% of deaths 
and 6% of lost disability-adjusted-life-years were due to hypertension.5 Although the 
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developed countries account for the bulk of economic costs of hypertension, this disorder is 
responsible for a large and increasing economic and health burden in developing countries, 
and we can expect that an ever-increasing proportion of the costs is going to be borne by 
those countries.6,7 For example, it has been predicted that the Asia Pacific region will bear 
about half of the world’s cardiovascular burden, and high blood pressure is an important 
determinant of cardiovascular disease.8 In China, the prevalence of hypertension has also 
been increasing over the past decade and in recent years reached as high as 39% among 
adults over age 35 years. Not surprisingly, the majority (62%) of strokes and about half 
(49%) of the cases of ischemic heart disease were attributable to hypertension.9,10 
Moreover, morbidity and mortality due to these 2 chronic conditions have been increasing 
rapidly in China in recent decades.11,12 Given recent trends in cardiovascular disease in 
China, hypertension control has become a public health priority in that nation.
Fortunately, many effective pharmacologic treatments have become available for outpatient 
control of high blood pressure. Inpatient care for hypertension and its complications is 
expensive, but many hospitalizations may be avoided with the use of antihypertensive 
drugs.13 The challenge is that patient adherence to antihypertensive medications remains 
poor in both developed and developing countries, and the lack of adherence to prescribed 
regimens constitutes a barrier to adequate blood pressure control and the prevention of 
cardiovascular events.14–18 In addition, some researchers have demonstrated that poor 
adherence to antihypertensive medications is associated with a higher risk of vascular events 
and hospitalization, and greater healthcare costs.16–18 An increased level of adherence to 
antihypertensive agents should result in a better health outcome for patients; therefore, 
providing a medication benefit may be a cost-effective policy option for improving 
population health.13,17,18 Many researchers have investigated strategies to improve patients’ 
adherence to medications in a cost-effective manner.19–23
Financial problems such as a lack of health insurance frequently affect patients’ ability to 
control hypertension because the medications are unaffordable for low-income, rural 
residents in both developed and developing countries.13,19,23 In 2 US studies, lower 
copayments for hypertension drugs were associated with improved adherence.20, 22 
However, there is limited evidence on the relationship between reducing the cost of 
hypertension medications and adherence to these medications, although studies have 
documented the growing problem of hypertension in rural China.24–26 To fill in this gap, we 
evaluated the effectiveness of a medication subsidy program in rural communities in 
Shandong Province, China, by conducting and analyzing a face-to-face interview survey of 
hypertensive patients. The effectiveness was measured by patients’ medication adherence 
status, economic burden of disease, and blood pressure levels.
BACKGROUND OF THE MEDICATION SUBSIDY PROGRAM
In 2007, the health department of Shandong Province developed an initiative, Rural Health 
Care Workers Training and Non-communicable Disease Control Programs, which was 
supported by the government of Luxembourg through collaborations with the World Health 
Organization. The initiative focused primarily on (1) training rural healthcare workers in 
chronic disease control and prevention and (2) improving rural residents’ awareness of 
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health risk factors and promoting a healthy lifestyle. Eight rural counties were selected to be 
the project counties. A baseline survey, which elicited information from families and also 
included a medical examination and laboratory testing, was conducted in the project 
counties from April 13 to May 1, 2007. This survey revealed that many patients with 
hypertension did not know the adverse health impacts of high blood pressure, and even if 
they had hypertension, they were not taking any antihypertensive drugs. These patients were 
more likely to have a low income and less likely to be able to afford antihypertensive drugs 
or obtain standard treatment. Overall, the rates of hypertension treatment and control were 
unacceptably low; thus, a program to subsidize the cost of medication was implemented in 
May 2008 in selected villages of all 8 counties.
DETAILS OF THE PROGRAM
The subsidy program provided basic medicines at no charge for hypertensive patients in 
low-income families, as well as standard treatment and management as needed. The basic 
medication regimen, the NAH (nifedipine, atenolol, hydrochlorothiazide) program, was 
recommended by the China National Hypertension League. More generally, the program 
had 3 components: (1) At the initial clinic visit, the patient received a standard dose of 
medication according to blood pressure level, age, and sex (eg, nifedipine 2.5 mg 3 times 
daily, atenolol 6.25 mg once daily, or hydrochlorothiazide 6.25 mg once daily). The patient 
was asked to have a follow-up visit in 3 to 5 days. (2) At follow-up, the drug regimen was 
adjusted if needed according to blood pressure control status and drug complications. (3) If 
the 3 drugs could not bring the blood pressure under control, angiotensin-converting enzyme 
inhibitors, angiotensin II receptor antagonists, angiotensin II receptor blockers, and other 
drugs were added as appropriate. The patients received the hypertension drugs at no charge 
from the clinicians, and the clinicians were reimbursed 150 Chinese yuan per year for every 
patient served by the Rural Healthcare Workers Training and Non-communicable Disease 
Control Programs. (The 150 yuan was usually enough to cover the costs of hypertension 
drugs for each patient for a year in the rural communities.) The 3 main outcomes of interest 
were patient’s medication adherence status, the economic burden of disease, and the blood 
pressure level. Medication adherence was determined by observing the patient’s medication-
taking behavior. The patient’s economic burden of disease was total medical costs of 
chronic diseases associated with hypertension, including inpatient, outpatient, and 
medication costs.
METHODOLOGY
In November 2009, about 18 months after the subsidy program began, a field survey in 2 
townships in Cangshan County, 1 of the intervention counties, was conducted by trained 
researchers and graduate students from School of Public Health, Shandong University. In 
both townships, 2 villages were randomly selected as the project intervention sites. All 
hypertensive patients living in the villages were included. The survey involved holding face-
to-face interviews with 110 hypertensive patients who received free hypertension drugs in 
the 4 villages (the intervention group) and 241 hypertensive patients of similar economic 
status who did not participate in the free medication program in 7 adjacent villages (the 
control group). A predesigned questionnaire covered major sociodemographic variables, 
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number of family members with high blood pressure, health complications, time since 
diagnosis, knowledge about hypertension, behaviors (following the doctor’s advice and 
taking medication), and inpatient and outpatient medical expenses. The survey was designed 
to evaluate the effectiveness of a medication subsidy for low-income rural patients with 
noncommunicable diseases. The survey contained 15 forms that were developed and pilot-
tested by a research team at Shandong University. We only analyzed the survey items 
related to hypertension (Appendix).
Blood pressure measurements were obtained from clinic technician records from 2009 (a 
year after the subsidy program began). Both systolic and diastolic blood pressures were 
measured twice in a 3- to 5-day interval. If either the systolic or diastolic measure differed 
by 6 or more mm Hg between the 2 measurements, a third measurement was taken. The 
average of the 2 or 3 measurements was recorded as the blood pressure level. Medical cost 
was collected from health insurance agencies and confirmed or supplemented by the face-to-
face interview.
We used a 1:1 propensity-score matching technique to obtain patients for the intervention 
and control groups based on the information from our survey.27–30 Because the intervention 
and control groups were not randomly selected, the distribution of characteristics among 
patients in the intervention group was quite different from that among patients in the control 
group, although we tried to select the patients with similar economic status in both groups 
(Table 1). It was possible that the distribution of their demographic characteristics (eg, age, 
sex, education) or of other factors could have biased our results when we compared the 2 
groups. Thus, to minimize the potential bias in the analysis, we derived the matched samples 
using a logistic regression model based on patients’ age, sex, education, marital status, 
economic status, health status, and insurance participation.27 Then, using the matched 
sample populations, we compared medication-taking behavior, medical costs, and blood 
pressure control status. We used the χ2 test for categorical variables and the Wilcoxon 2-
sample test for continuous variables. All tests of statistical significance were 2-tailed, and 
because our study samples were small, we considered P <.05 to indicate a significant 
difference. The SAS statistical package (Version 9.1, SAS, Cary, North Carolina) was used 
for all of the analyses.
RESULTS
Before the propensity-score matching, 5 variables were found to differ significantly by 
group (Table 1): education, per capita income, health complications, time since patient was 
first diagnosed with hypertension, and knowledge of the relationship between hypertension 
and diet. These differences, if left uncorrected, would have biased the comparison analysis 
of medication-taking behaviors, medical costs, and blood pressure levels. After propensity-
score matching, the 5 significant distribution differences in the population characteristics 
(Table 1) were greatly reduced, and only 1 of these characteristics, health complications (P 
<.05), differed significantly between the intervention and control groups (Table 2). Thus, the 
2 groups were now comparable and could be used for the comparison analysis.
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Patients who received a medication subsidy were more likely to take some prescribed drugs 
for hypertension control than were unsubsidized patients (P <.001; Table 3). In the 
intervention group, every patient took at least 1 prescribed drug for hypertension and 93.1% 
took 3 or more such drugs. In contrast, 14.7% of control group patients took no prescribed 
hypertension drugs at all and only 39.2% took 3 or more of these drugs.
In the intervention group, the percentage of patients who always took a prescribed 
hypertension drug and the percentage who took such drugs most of the time were higher 
than they were in the control group, but the difference in the overall pattern (taking 
medication regularly) was only significant at the P <.05 level (P = .034). For patients who 
did not regularly take a blood pressure medication, the main reason in both groups was “not 
feeling sick” followed by “forgetting.” The samples here were much smaller than for the 
other 2 items, and the overall difference between the intervention and control groups was not 
statistically significant (P = .782).
Annual out-of-pocket medical costs (including inpatient, outpatient, and medications) were 
significantly lower for patients in the intervention group than for those in the control group 
(575 Chinese yuan vs 688 yuan; P <.001) (Table 4). In addition, the median for total out-of-
pocket costs was far lower for patients receiving the subsidy (120 yuan vs 228 yuan). The 
difference in out-of-pocket costs for outpatient visits, including medications, was significant 
(192 yuan vs 380 yuan; P <.001). Finally, the out-of-pocket costs as a percentage of family 
income were much lower for patients receiving the subsidy (12.3% vs 27.7%; P <.001).
Both systolic and diastolic blood pressures were not significantly lower for patients in the 
intervention group compared with the control group (P = .379 and P = .544, respectively) 
(Table 5). Similarly, the proportion of patients with their hypertension under control was not 
significantly different between the intervention and control groups (P = .831).
DISCUSSION
By developing statistically similar samples for intervention and control groups using the 
propensity-score matching technique, we were able to estimate the effects of a drug subsidy 
program by comparing the outcomes of the 2 groups at a single time point. In that way, our 
study is different from other studies, which usually estimate a program’s effect by 
comparing data from before and after the intervention.31,32 Further, our use of the 
propensity-score matching method was only one of the analysis’s strengths. For example, 
our study may be the first to investigate the effect on hypertension control in China of 
providing financial incentives directly to patients. Our results suggest that the subsidy 
increased medication adherence, which is consistent with evidence from abroad.13,20,22 
Moreover, although blood pressure measurements were not significantly lower for patients 
in the intervention group compared with patients in the control group, they were much lower 
than the blood pressure measurements before the intervention (in 2007). Thus, policy 
makers in China should consider subsidizing necessary drugs when they are developing 
hypertension control policies.
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Another strength is that we collected information not only on medication-taking behavior, 
but also on relevant variables such as socioeconomic status, medical costs, and health status. 
Thus, the survey instrument we used might be useful for investigating the impacts of other 
health intervention programs such as initiatives to reduce sodium intake or to prevent stroke 
and diabetes, all of which are significant public health issues in today’s China. “Not feeling 
sick” was the main reason for not regularly taking the medication in both the intervention 
and the control groups, which may suggest a need for further patient education. Finally, our 
results suggest that the medication subsidy reduced the total economic burden of chronic 
diseases for the patients, which is consistent with findings in developed 
countries.17,18,20,22,33,34 This suggests a solid economic return from the intervention.
Its strengths notwithstanding, our study had several limitations that may limit its application 
to other settings. First, because the funding for our research was limited, we could interview 
only a small number of patients in the intervention and control villages for the evaluation. 
The relatively small sample might help to explain why some of our results were not 
statistically significant. Second, also because of our small sample, we conducted only 
univariate analyses; thus, we could not examine the effect of potential confounders on the 
program’s impact. Correspondingly, we did not know how much of the difference in 
medication-taking behaviors and medical costs between the intervention and control groups 
was actually attributable to the subsidy program. More data and approaches using advanced 
econometric models would be required for such an evaluation. Finally, our evaluation period 
was too short to investigate the program’s linkage to the incidence of health complications 
such as heart attack and stroke. We should also note that although patients’ adherence to 
medication increased, their blood pressure levels did not decrease significantly. This might 
be in part because our sample was too small or because there was insufficient intensification 
of medications. Further investigation on the impact of a drug subsidy on blood pressure 
levels and associated complications such as heart attack and stroke should be carried out in 
the future.
CONCLUSIONS
Our evaluation of a subsidy program focused on prescribed hypertension drugs indicates that 
it improved patients’ adherence to taking such medication and reduced their financial burden 
in several different ways. Because poor adherence to medication regimens is common and 
the cost of medication is a major predictor of poor adherence,21,22,35–37 subsidizing the costs 
of hypertension drugs may be a cost-effective policy option if it can reduce the 
complications of hypertension, prevent a large number of deaths, and contain the growing 
healthcare costs through a reduction in blood pressure. However, more economic research is 
needed to produce the evidence that such an intervention would be cost-effective in both 
developed and developing countries.
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Appendix. Evaluation of the Policy Entitled Free Medicine for Low-income 
Patients With Non-communicable Disease
Questionnaire for household survey
1. Name of the patient: __________ Patient code: __________
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2. Address of the household: County Township Village: ______________
3. Tel No. of the patient: ______________
4. Name of the interviewer: __________ Interviewer code: ______________
5. Date of survey: (year) (month) (day)
Table 1
Patient’s General Information (If the patient is not available, other family member who 
knows him/her well should answer the survey)
1 Is the questionnaire answered by the patient? (1) Yes; (2) No, please specify the relationship between the 
patient and the interviewee
2 Gender: (1) Male; (2) Female
3 Age (years):
4 Ethnicity: (1) Han; (2) Other, please specify
5 Marital status: (1) Never married; (2) Married; (3) Divorced/Widowed
6 Education: (1) < Elementary school; (2) < Middle school; (3) < High school, technical school, and technical 
secondary school; (4) < College; (5) ≥ College
7 Main occupation: (1) Farmer; (2) Factory worker; (3) Village manager; (4) Technical personnel; (5) School 
teacher; (6) Village doctor; (7) Army staff; (8) Commercial business; (9) Immigration workers within the 
county; (10) Immigration workers outside the county; (11) Student; (12) Preschool child; (13) Other, please 
specify
8 Which health plan do you have? (1) None; (2) New rural cooperative medical scheme; (3) Government 
employee plan; (4) Labor and semilabor plan; (5) Basic insurance plan for employees in urban areas; (5) 
Private insurance plan; (7) Other, please specify
Table 2
Health Awareness and Knowledge About Hypertension and Diabetes
1 Do you think diet is associated with high blood pressure? (1) Yes; (2) No; (3) Unknown
2 Do you think diet is associated with diabetes? (1) Yes; (2) No; (3) Unknown
3 Do you think smoking is associated with high blood pressure? (1) Yes; (2) No; (3) Unknown
4 Do you think smoking is associated with diabetes? (1) Yes; (2) No; (3) Unknown
5 Is adiposity or overweight associated with high blood pressure? (1) Yes; (2) No; (3) Unknown
6 Is adiposity or overweight associated with diabetes? (1) Yes; (2) No; (3) Unknown
Table 3
Family Economic Status (should be answered by the member who knows the household 
most well)
1 How much were the household production costs (for farmers, this means the direct input into agriculture, ie, 
expenditure for seeds, fertilizer, pesticide, annual cost of farming machines, etc) in 2008?
2 How much were the household living expenditures in 2008?
2.1 Food expenditure:
3 Expenditures for clothing and other daily life items:
4 Expenditures for transportation and communication:
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5 Expenditure for housing, electricity, water, and fuel:
6 Expenditures for culture, education, and entertainment:
7 Expenditures for drugs, healthcare, and medical supplies:
8 Expenditure for other household items:
9 Does the household have any debt or loan? (1) Yes; (2) No; (3) No answer
9.1 If yes, how much is it?
9.2 If yes, what is the main reason that led the household into debt? (1) Lack of labor; (2) Natural disaster; (3) 
Disease or injury; (4) Education; (5) Marriage; (6) Other, please specify
10 How do you consider the household’s economic status in the village? (1) High income; (2) Above average; 
(3) Average; (4) Below average; (5) Poor
*
The relationship of the respondent to the patient: (1) Self; (2) Spouse; (3) Parent; (4) Other, please specify
Table 4
Situations Related to Prescribed Medications for Patients With Hypertension (people with 
high blood pressure, please continue to Tables 4–8)
1 Your date of diagnosis of high blood pressure (year/month)
1.1 Where was the diagnosis performed?
(1) Village health clinic; (2) Private clinic; (3) Township health center; (4) County-level hospitals; (5) 
Hospitals above county level; (6) No diagnosis; (7) Other, please specify
2 The severity of your high blood pressure symptoms: (1) No symptoms; (2) Mild discomfort, symptoms do 
not affect the normal working life; (3) Moderate discomfort, not able to do some work, but symptoms do 
not affect the daily living; (4) Unable to work; (5) Severe discomfort, stay in bed
2.1 Do you have other complications of high blood pressure (eg, coronary heart disease, stroke, hypertensive 
heart disease, nephropathy)? (1) No; (2) Yes
2.2.1 What is the classification of your high blood pressure? (1) I; (2) II; (3) III; (4) Unknown
2.2.2 How much can you control your blood pressure to now? (1) Control to mm Hg/mm Hg; (2) Unknown
2.2.3 How much was your blood pressure when it was tested lately?
2.2.4 Do you know the range of normal blood pressure? (1) Yes, is mm Hg/mm Hg; (2) No
2.2.5 Judged by the investigator, whether the patients’ answer to normal blood pressure range is right? (1) Yes; 
(2) No
3.1.1 After being diagnosed with high blood pressure, how often should you measure your blood pressure 
according to the doctor’s advice? (1) Once a day; (2) At least once a week; (3) At least once a month; (4) 
At least once a season; (5) No need to measure; (6) Not told by doctor; (7) Other, please specify
3.1.2 After being diagnosed with high blood pressure, how often do you measure your blood pressure? (1) Once 
a day; (2) At least once a week; (3) At least once a month; (4) At least once a season; (5) No need to 
measure; (6) Not told by doctor; (7) Other, please specify
3.1.3 What is the main reason why you do not regularly monitor the blood pressure and have periodic 
reexamination? (1) Disease is not serious, no need to; (2) Family financial difficulties; (3) Too much 
trouble, do not have the time; (4) Do not know how to monitor blood pressure and periodic reexamination; 
(5) Already have the disease, no matter what; (6) Other, please specify
3.2.1 After you were diagnosed with high blood pressure, did the doctor tell you that you should not smoke? (1) 
Nonsmoker; (2) Yes; (3) No; (4) Unclear; (5) Other, please specify
3.2.2 After you were diagnosed with high blood pressure, did the doctor tell you that you should limit drinking 
alcohol? (1) Nondrinker; (2) Yes; (3) No; (4) Unclear; (5) Other, please specify
3.2.3 After you were diagnosed with high blood pressure, did the doctor tell you that you should adjust or control 
diet? (1) Yes; (2) No; (3) Unclear; (4) Other, please specify
3.2.4 After you were diagnosed with high blood pressure, did the doctor recommend that you get appropriate 
physical activity? (1) Yes; (2) No; (3) Unclear; (4) Other, please specify
3.3 Has the doctor asked you to take medicine therapy? (1) Yes; (2) No
Yu et al. Page 10
Am J Manag Care. Author manuscript; available in PMC 2015 August 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
3.3.1 Did the doctor tell you that you should take medication consistently to control your blood pressure? (1) 
Yes; (2) No; (3) Don’t remember
3.4 Does anyone in your family (parents and siblings) have hypertension? (1) Yes; (2) No; (3) Not clear
Table 5
Medication Utilization for Patients with Hypertension
1.1 How many kinds of medications are you taking?
1.2 The medications you are taking are:
The first: ___
The second: ___
The third: ___
2 Do all the medications you are taking now belong to the prescribed list (meaning that you can apply for 
reimbursement from the new Rural Cooperative Medical Scheme [RCMC])? (1) Yes; (2) No; (3) Don’t know 
If you choose (2), please answer questions 2.1 and 2.2, otherwise skip to question 3 immediately
2.1 Why did you choose the medication that is not on the prescribed list? (1) Better effect; (2) Doctor’s 
suggestion; (3) Other, please specify
2.2 Given that medications not on the prescribed list cannot be reimbursed by RCMC or by the project (Free 
Medicine for Low-income Patients With Non-communicable Disease), do you think that the cost will 
influence your treatment decisions? (1) Yes; (2) No; (3) Have no idea
3 Are you taking your hypertension medication regularly? (1) Always; (2) Most times; (3) Sometimes; (4) 
Only take medication when it comes to mind; (5) Only take medication when feeling uncomfortable
3.1 Do you know that taking medications regularly is beneficial to control your disease? (1) Yes; (2) No
3.2 What is the biggest obstacle that prevents you from taking medication regularly? (1) Not applicable; (2) No 
uncomfortable feeling; (3) Too busy or forget; (4) Other, please specify
4 Do you take medications according to doctor’s orders? (1) Take medications according to the quantities 
suggested; (2) Take more medications than the quantities suggested; (3)Take fewer medications than the 
quantities suggested; (4) Based on health status, take more or fewer medications; (5) Other, please specify
Table 6
Implementation of the Free Medicine for Low-income Patients With Non-communicable 
Disease Policy and Patient Attitudes (if you were covered by the free medicine policy, then 
please fill in this form)
1.1 Are you satisfied with the free medicine policy for poor patients with non-communicable disease (including 
the implementation plan and the amount of the compensation)? (1) 100% satisfaction; (2) 80% satisfaction; 
(3) 50% satisfaction; (4) 20% satisfaction; (5) Not satisfied
1.2 Can you give any comments about the policy?
1.3 Do you know that how much money you can get from the project (patients in counties other than Cangshan 
country)? (1) Understand totally, and say the specific number; (2) Know a little information; (3) Unknown
1.4 What kind of medicines can you get for free from the project? (patients in Cangshan county)
Table 7
Cost of Outpatient Care for Patients With Hypertension
1 How much do you currently spend for medications to control blood pressure every month?
2 How much did you spend in 2008 to treat your hypertension and its complications?
2.1 How much was covered by the New Rural Cooperative Medical Scheme?
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2.2 How much was covered by other health plans?
2.3 How much was covered by the project?
3 At which facility did you primarily purchase medications? (1) Drugstore; (2) Village clinic; (3)Township 
health center; (4) County hospital; (5) Other, please specify
3.1 Why did you choose this facility? (1) Close to my house; (2) Low price; (3) Covered by health plans; (4) 
Other, please specify
4 When was the last time you saw a doctor for hypertension? (1) < 1 month; (2) 1–2 months; (3) 2–3 months; 
(4) 3–6 months; (5) 6–12 months; (6) >12 months
4.1 Where did you see a doctor for hypertension the last time? (1) Village clinic; (2) Private clinic; 
(3)Township health center; (4) County hospital; (5) Other, please specify
4.1.1 Why did you select that institution? (1) Close to my home; (2) Low price; (3) Good quality; (4) It is 
assigned; (5) Friends work there; (6) Have reliable doctors; (7) Staff are kind; (8) Recommended by 
someone; (9) Other, please specify
4.2 What were the total medical charges from this institution?
4.2.1 How much was covered by public health plans?
4.2.2 How much was covered by private health plans?
4.2.3 How much was covered by this project?
5 Have you been hospitalized because of hypertension or a related complication the last year? (1) Yes; (2) No
6 Last year, did a doctor recommend that you be hospitalized because of hypertension or a related 
complication, but you rejected hospitalization? (1) Yes; (2) Was hospitalized according the doctor’s order
6.1 If you refused the inpatient service, why did you refuse (single choice)? (1) Did not perceive illness severe 
enough; (2) No time; (3) Financial difficulty; (4) Poor service quality of the hospital; (5) No bed available; 
(6) Too far, lack of transportation; (7) Other, please specify
Table 8
Hospitalization of Patients With Hypertension Last Year (if the patient was not hospitalized, 
please do not fill this form)
1 The primary reason you were in the hospital: (1) Hypertension; (2) Coronary heart disease; (3) Myocardial 
infarction; (4) Cerebral infarction; (5) Cerebral hemorrhage; (6) Hypertensive renal disease; (7) Hypertensive 
heart disease; (8) Other, please specify
2 How many times have you been in the hospital for this disease last year?
3 Where were you hospitalized? (1) Township health center; (2) County hospital; (3) Prefecture hospital; (4) 
Other, please specify
4 Why did you select that institution? (1) Close to my home; (2) Low price; (3) Good quality; (4) It is assigned; 
(5) Friends work there; (6) Have reliable doctors; (7) Staff are kind; (8) Recommended by someone; (9) 
Other, please specify
5 What was the length of your stay in the hospital (days)?
6 What were the total medical charges (hospitalization, drugs, supplies, etc) for these hospitalizations?
6.1 How much of the charges were covered by public health plan?
6.2 How much of the charges were covered by other health plans?
6.3 How much was spent on transportation and food related to these hospitalizations?
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Table 9
Field Measurement of Blood Pressure
Did you take any medicine like hypotensor, vasodilator drug, diuretic, or 
sedative drugs today □Yes □No
SBP1/DBP1: the first measurement SBP1:  mm Hg, DBP1:  mm 
Hg
SBP2/DBP2: the second measurement SBP2:  mm Hg, DBP2:  mm 
Hg
If the difference between SBP1 and SBP2 or DBP1 and DBP2 is equal to or 
more than 6 mm Hg, please measure the third time: SBP3/DBP3
SBP3:  mm Hg, DBP3:  mm 
Hg
Signature of the surveyor
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Take-Away Points
In both developed and developing countries, the control rate for hypertension is 
unacceptably low, and poor adherence to medication is a primary reason.
• A free medication program is effective in improving adherence and reducing 
total medical costs in rural communities in China.
• The impact of the program on blood pressure levels and disease outcomes 
requires further investigation.
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Table 1
Characteristics of the Intervention (n = 110) and Control (n = 241) Groups Before Matching of the Samples
Characteristic
No. (%)
χ2 or t Test (P)Intervention Group Control Group
Male 50 (45.5) 129 (53.5) 1.97 (.161)
Age, y
 <55 24 (21.8) 37 (15.4) 3.50 (.321)
 55–64 31 (28.2) 69 (28.6)
 65–74 32 (29.1) 90 (37.3)
 ≥75 23 (20.9) 45 (18.7)
Education
 <Elementary 80 (72.7) 123 (51.0) 14.65 (.001)
 Elementary to middle school 15 (13.6) 63 (26.1)
 >Middle school 15 (13.6) 55 (22.8)
Marital status
 Never married 1 (0.9) 6 (2.5) 0.99 (.611)
 Married 87 (79.1) 186 (77.2)
 Widowed 22 (20.0) 49 (20.3)
Farmers 102 (92.7) 209 (86.7) 2.70 (.101)
New cooperative medical coverage 103 (93.6) 226 (93.8) 0.003 (.960)
Annual per capita income, yuan
 <2300 52 (49.1) 56 (23.9) 21.27 (<.001)
 2300–4199 25 (23.6) 80 (34.2)
 ≥4200 29 (27.4) 98 (41.9)
Number of family members having hypertension
 At least 1 43 (39.1) 98 (40.7) 1.63 (.442)
 None 52 (47.3) 121 (50.2)
 Unknown 15 (13.6) 22 (9.1)
Health complications
 Yes 87 (79.1) 155 (64.3) 8.99 (.011)
 No 18 (16.4) 76 (31.5)
 Unknown 5 (5.4) 9 (3.7)
Time since first diagnosed with hypertension, y
 <4 47 (43.5) 75 (31.9) 11.31 (.004)
 4–10 43 (39.8) 80 (34.0)
 ≥11 18 (16.7) 0 (34.0)
Health awareness
 Hypertension and diet 87 (77.8) 142 (62.8) 7.46 (.006)
 Hypertension and smoking 76 (70.4) 137 (60.6) 3.01 (.083)
 Hypertension and body weight 64 (59.3) 122 (54.0) 0.83 (.364)
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Characteristic
No. (%)
χ2 or t Test (P)Intervention Group Control Group
 Hypertension and regular medication 101 (91.8) 205 (95.8) 2.19 (.139)
Systolic blood pressure in 2007 (mm Hg, mean ± SE) 161.8 ± 18.9 160.2 ± 23.6 0.61 (.540)
Diastolic blood pressure in 2007 (mm Hg, mean ± SE) 91.8 ± 12.1 92.1 ± 11.8 0.19 (.849)
SE indicates standard error.
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Table 2
Characteristics of the Intervention (n = 102) and Control (n = 102) Groups After Matching of the Samples
Characteristic
No. (%)
χ2 or t Test (P )Intervention Group Control Group
Male 46 (45.1) 49 (48.0) 0.177 (.674)
Age, y
 <55 24 (23.5) 15 (14.7) 3.45 (.327)
 55–64 29 (28.4) 27 (26.5)
 65–74 29 (28.4) 38 (37.3)
 ≥75 20 (19.6) 22 (21.6)
Education
 <Elementary 74 (72.5) 66 (64.7) 1.89 (.388)
 Elementary to middle school 14 (13.7) 21 (20.6)
 >Middle school 15 (13.7) 15 (14.7)
Marital status
 Never married 1 (1.0) 0 (0) 3.78 (.151)
 Married 84 (82.4) 75 (73.5)
 Widowed 17 (16.7) 27 (26.5)
Farmers 94 (92.2) 93 (91.2) 0.06 (.800)
New cooperative medical coverage 95 (93.1) 98 (96.1) 0.87 (.352)
Annual per capita income, yuan
 <2300 51 (50.0) 41 (40.2) 2.34 (.310)
 2300–4199 23 (22.5) 31 (30.4)
 ≥4200 28 (27.5) 30 (29.4)
Number of family members having hypertension
 At least 1 41 (40.2) 33 (32.4) 1.48 (.477)
 None 48 (47.1) 56 (54.9)
 Unknown 13 (12.7) 13 (12.7)
Health complications
 Yes 81 (79.4) 66 (64.7) 9.30 (.010)
 No 16 (15.7) 34 (33.3)
 Unknown 5 (4.9) 2 (2.0)
Time since first diagnosed with hypertension, y
 <4 44 (43.1) 43 (42.2) 1.73 (.421)
 4–10 42 (41.2) 36 (35.3)
 ≥11 16 (15.7) 23 (22.5)
Health awareness
 Hypertension and diet 79 (77.5) 75 (73.5) 0.42 (.515)
 Hypertension and smoking 73 (71.6) 64 (62.7) 1.80 (.180)
 Hypertension and body weight 61 (59.8) 53 (52.0) 1.27 (.259)
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Characteristic
No. (%)
χ2 or t Test (P )Intervention Group Control Group
 Hypertension and regular medication 94 (92.2) 96 (94.1) 0.31 (.580)
Systolic blood pressure in 2007 (mm Hg, mean ± SE) 161.5 ± 19.3 160.3 ± 23.4 0.42 (.679)
Diastolic blood pressure in 2007 (mm Hg, mean ± SE) 92.1 ± 12.4 90.2 ± 11.6 1.09 (.28)
SE indicates standard error.
Am J Manag Care. Author manuscript; available in PMC 2015 August 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Yu et al. Page 19
Table 3
Comparison of Hypertension Medication Status Between Intervention (N = 102) and Control (N = 102) 
Groups
Medication Status
No. (%)
PIntervention Group Control Group
Taking prescribed medication
 No 0 (0) 15 (14.7) <.001
 1 or 2 types of drugs 7 (6.9) 47 (46.1)
 ≥3 types of drugs 95 (93.1) 40 (39.2)
Taking prescribed medication regularly
 Always 76 (74.5) 67 (65.7) .034
 Most of the time 9 (8.8) 5 (4.9)
 Some of the time 10 (9.8) 5 (4.9)
 When feeling sick 7 (6.9) 10 (9.8)
 Never 0 (0) 15 (14.7)
Reasons for not regularly taking medication n = 26 n = 35
 Cannot afford 1 (3.8) 2 (5.7) .782
 Not feeling sick 16 (61.5) 25 (71.4)
 Forgetting 7 (26.9) 6 (17.1)
 Other 2 (7.7) 2 (5.7)
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Table 4
Comparison of Annual Medical Costs (Chinese Yuan) for Patients With Hypertension
Annual Medical Costs
Mean ± SE (Median), Yuan
PIntervention Group (n = 98) Control Group (n = 94)
Out-of-pocket costs, including inpatient, outpatient, and medications 574.5 ± 1933.8 (162.0) 687.8 ± 1303.7 (228.0) <.001
Out-of-pocket costs for outpatient visits, including medications 191.9 ± 443.4 (157.0) 380.0 ± 552.8 (200.0) <.001
Total out-of-pocket costs as a percentage of family income 12.3 ± 32.6 (5.0) 27.7 ± 58.2 (8.6) <.001
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Table 5
Blood Pressure Control Status of Intervention (n = 102) and Control (n = 102) Groups
Control Status Intervention Group Control Group P
Blood pressure, mm Hg, mean ± SE
 Systolic 151.2 ± 16.5 153.4 ± 18.4 .379
 Diastolic 87.1 ± 12.2 88.1 ± 9.9 .544
Under control, n (%) 13 (12.7) 12 (11.8) .831
Uncontrolled, n (%) 89 (87.3) 90 (88.2)
SE indicates standard error.
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